Abiomed (NSDQ:ABMD) said today that the Centers for Medicare & Medicaid Services plan to maintain the reimbursement rate for treatment with its Impella heart pump when new rates go into effect this fall.
Wall Street Beat
IsoRay drops hard on news of $14.7M direct offering
Wall Street give IsoRay Medical’s (AMEX:ISR) shares a beating today after the company announced that it had sold about $14.7 million in common stock to a pair of unnamed institutional investors.
Presbia files for $90M IPO
Presbia, which makes the Flexiview Micro-Lens corneal implant to treat presbyopia, registered with the SEC for an initial public offering of up to $90 million worth of stock.
The Flexiview Micro-Lens is designed to be inserted into a pocket created in the cornea using a laser. The pocket seals itself, holding the 3mm-diameter lens in the center of the visual axis. The 10-minute procedure is reversible and does not require general anesthesia, according to Presbia’s website.
K2M Group Holdings looks to raise $100M in IPO | Medtech Wall Street stories for the week of Mar. 17, 2014
Proxy war brews as activist investor Oracle targets Biolase board
ConMed delays annual meeting amid proxy war
Spinal firm K2M aims for $100M IPO
Spinal surgery devices maker K2M Group Holdings hopes to raise as much as $100 million through its impending initial public offering, according to registration documents filed with the SEC.
Biomet puts itself back on public market | Medtech Wall Street news for the week of Mar. 10, 2014
Biomet announces IPO plans
March 7, 2014 by Brad Perriello
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
Vital Therapies revives delayed IPO, tallies $14M funding round
Bio-artificial liver maker Vital Therapies is prepared to take another run at its initial public offering, months after deciding to put off the IPO to await more favorable market conditions.
The California biotech company filed updated registration statements signaling its intent to launch the IPO, wiping clean the pricing set in November 2013. The new offering cap and per-share pricing have yet to be announced.
Siemens, GE named among worst-performing device makers of the year | MassDevice.com On Call
MASSDEVICE ON CALL — Medtech giants have seen Wall Street bumps so far this year, but several of the company’s in the industry’s top 40 haven’t been so fortunate.
TriVascular Tech aims for $100M IPO
California medical device maker TriVascular Technologies is looking to raise as much as $100 million through its initial public offering, the details of which have yet to be finalized.